Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04916470 · ClinicalTrials.gov registry record · Phase 3
Research Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity and Type 2 Diabetes
A Phase 3 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 3
- Development phase
- 617
- Enrollment target
NCT04916470: Completed Phase 3 study, sponsored by Novo Nordisk A/S.
NCT04916470 is a Phase 3 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 617 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (20% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04916470, a Phase 3 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 617 participants
- Enrollment target
Study Summary
This study will look at how participants' daily life is affected by their heart failure. The study will also look at the change in participants' body weight. This study will compare the effect of semaglutide (a new medicine) compared to "dummy" medicine on body weight and heart failure symptoms. Participants will either get semaglutide or "dummy" medicine, which treatment participants get is decided by chance. Participants will need to take 1 injection once a week. The study medicine is injected with a thin needle in a skin fold in the stomach area, thigh or upper arm. During the study participants will have talks with the study staff about healthy lifestyle and physical activity. The study will last for about 59 weeks, that is a little more than 1 year. Participants will have 12 clinic visits with the study doctor. * At 6 of the visits participants will have blood samples taken. * At 5 of the visits participants will be asked to fill in a questionnaire * At 4 of the visits participants will have to do a 6-minute walking test * At 3 of the visits participants will have a test to check the heart. * participants will have their eyes checked before or at the start of the study and at the end of the study Women cannot take part if pregnant, breast-feeding or plan to become pregnant during the study period.
Primary Outcome
Score on a scale of 0 to 100 where the score 100 means the least burden for the participant.
Interventions
- DRUG Semaglutide
- DRUG Placebo (Semaglutide)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 617 participants |
| Start Date | 2021-06-15 |
| Est. Completion | 2023-10-11 |
| Phase | Phase 3 |
What the finished NCT04916470 record still lists
NCT04916470 is an interventional study that assigns participants to a tested intervention. The registered 617 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (20% lower).
The record links to 0 conditions, and to 2 interventions - of which Semaglutide is the first listed.
NCT04916470 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04916470 about?
NCT04916470 is a clinical study titled "Research Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity and Type 2 Diabetes". This study will look at how participants' daily life is affected by their heart failure. The study will also look at the change in participants' body weight. This study will compare the effect of semaglutide (a new medicine) compared to "dummy" medicine on body weight and heart failure symptoms. P...
What is the current status of trial NCT04916470?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 617 participants. The study started on 2021-06-15. Estimated completion is 2023-10-11.
What interventions are being tested in trial NCT04916470?
The interventions under investigation include: Semaglutide (DRUG), Placebo (Semaglutide) (DRUG).
Who is sponsoring clinical trial NCT04916470?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04916470's enrollment target sits among peer trials
617 592nd of 2000 higher than 1,408 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02610179 · 617 participants · NA
Strawberry Candy Twists as an Alternative Screen for Gestational Diabetes: A Prospective Trial
- NCT05672927 · 618 participants · Phase 4
Comparing Immune Response of 2 vs 3 HPV Doses (27-45 Years Old)
- NCT06220721 · 618 participants · NA
Reducing the Risk of Chronic Hypertension and Improving Vascular Function Following Preeclampsia
- NCT04813185 · 616 participants · NA
Preventing Retaliatory Gun Violence in Violently Injured Adults
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI